If you would like to be added to the news release distribution list, please fill out the email alerts form here
2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005
| September 16, 2011 | Helix BioPharma Corp. To Present At The Twenty Seventh International Papillomavirus Conference And Clinical Workshop |
|---|---|
| July 25, 2011 | Helix BioPharma Corp. Receives Regulatory Approval To Conduct A European Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 |
| June 30, 2011 | Helix BioPharma Corp. To Present At The Fourteenth World Conference On Lung Cancer In Amsterdam On July 5th, 2011 |
| June 7, 2011 | Helix BioPharma Corp. Announces Fiscal Q3 2011 Results |
| March 31, 2011 | Helix BioPharma Announces Private Placement For Net Proceeds Of $2.0 Million |
| March 28, 2011 | Helix BioPharma Announces $3.9 Million Private Placement |
| March 23, 2011 |
Helix BioPharma Corp. To Present At Bit Life Science’ Third Annual International Congress Of Antibodies In Beijing China On March 25 |
| March 4, 2011 | Helix BioPharma Corp. Announces Fiscal Q2 2011 Results |
| March 2, 2011 | Helix BioPharma Corp. Reports That A U.S. Patent Has Been Issued For The Lung Cancer-Specific Antibody Used In Its Drug Candidate L-DOS47 |
| February 24, 2011 | Helix BioPharma Corp. Files European Clinical Trial Application For A Phase I/II Study Of Its Lung Cancer Drug Candidate L-DOS47 |
| February 9, 2011 | Helix BioPharma Corp. To Present at the Third International Conference on Drug Discovery and Therapy in Dubai on February 10. |
| February 7, 2011 | Helix BioPharma Corp. Receives FDA IND Approval to Conduct a U.S. Phase I Clinical Study with Its Lung Cancer Drug Candidate L-DOS47 |
| January 7, 2011 | Helix BioPharma Corp. Files IND for a U.S. Phase I Clinical Study of Its Cancer Drug Candidate L-DOS47 |
| December 10, 2010 | Helix BioPharma Corp. Announces Fiscal Q1 2011 Results |
| December 9, 2010 | Helix BioPharma Reports on 2010 Annual General and Special Meeting |
| November 19, 2010 |
Helix BioPharma Corp. Provides Update On Phase II/III IND Application For Topical Interferon Alpha-2b |
| October 29, 2010 | Helix BioPharma Corp. Announes Fiscal 2010 Results |
| October 21, 2010 |
Helix BioPharma Corp. Reports Positive Efficacy And Safety Findings From Phase II Study Of Its Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions |
| October 19, 2010 |
Helix BioPharma Corp. Retains CFSG1 As Its Exclusive U.S. Investor Relations Firm |
| October 19, 2010 |
Helix BioPharma Corp. Files IND For Its Planned Phase II/III Efficacy Trial Of Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions |
| October 12, 2010 | Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 And Is Making Final Preparations For Its Planned PHASE I/II Clinical Study IND/CTA Submissions |
| September 14, 2010 | HELIX BIOPHARMA APPROVED FOR NYSE AMEX LISTING |
| August 6, 2010 | Helix BioPharma Closes $11.0 Million Private Placement |